Fecal Calprotectin Test Market Poised To Witness High Growth Owing To Increase In Demand For Non-Invasive Diagnostic Tests
Fecal Calprotectin Test Market Poised To Witness High Growth Owing To Increase In Demand For Non-Invasive Diagnostic Tests
The global fecal calprotectin test market is estimated to be valued at US$ 161.98 Mn in 2024 and is expected to exhibit a CAGR of 3.9% over the forecast period 2024 to 2030.

The fecal calprotectin test market has experienced substantial growth globally in recent years owing to the rising demand for non-invasive diagnostic tests for gastrointestinal diseases. Fecal calprotectin is a protein found in the cytoplasm of neutrophils. It plays a crucial role in recognizing gastrointestinal inflammation and infection. The fecal calprotectin test aids in detecting inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease. It serves as a better alternative to endoscopic testing and colonoscopy for determining gut inflammation. The global fecal calprotectin test market is estimated to be valued at US$ 161.98 Mn in 2024 and is expected to exhibit a CAGR of 3.9% over the forecast period 2024 to 2030.

Key Takeaways
Key players operating in the fecal calprotectin test market are John Deere, Vermeer Corporation, Kuhn Group, AGCO Corporation, Krone North America, New Holland Agriculture, Claas Group, Kubota Corporation, Fella Maschinenbau GmbH, Sitrex S.p.A., Deutz-Fahr, Enorossi, Tonutti, Galfre, Pottinger Agricultural Machinery. These players are focusing on partnerships and new product launches to increase their market share.

The key opportunities in the fecal calprotectin test market include increasing cases of gastrointestinal disorders due to sedantry lifestyle, rising healthcare expenditure, and growing demand for point-of-care testing. In addition, advancement in rapid diagnostic tests will boost market growth over the forecast period.

Global expansion represents a major growth strategy adopted by the players in the fecal calprotectin test market. Market leaders are focusing on emerging markets in Asia Pacific and Latin America witnessing increasing incidences of IBD. Establishing manufacturing and distribution partnerships with regional companies enables global players strengthen their presence internationally.

Market Drivers
The rising prevalence of gastrointestinal disorders like IBD owing to changing dietary patterns, lack of physical activity, and increasing stress levels is a major market driver. According to a report by Crohn’s & Colitis Foundation, IBD affects over 3 million people in the U.S. as of 2020. Early diagnosis of the condition can prevent disease progression. This factor augments the demand for fecal calprotectin tests.

Market Restraints
High costs associated with fecal calprotectin diagnostic kits limiting their access in low and middle-income countries. Lack of awareness regarding these tests in underdeveloped regions further challenges market growth. Stringent regulatory framework for approving new products also acts as a market restraint.

Segment Analysis
The Fecal Calprotectin Test Market Demand  is dominated by the laboratory testing segment. Fecal calprotectin tests conducted in laboratories provide reliable and accurate results through automated testing methods. They help in timely detection of inflammation and enable clinicians to appropriately manage patients with gastrointestinal conditions.

The point-of-care testing segment is emerging in the fecal calprotectin test market owing to the rising preference for portable and convenient diagnostic options by patients. Point-of-care tests provide rapid results outside conventional laboratory settings and facilitate quick clinical decision making. Self-collection home tests are also gaining demand due to the flexibility and privacy offered to users.

Global Analysis
The North American region holds the largest share in the global fecal calprotectin test market due to the presence of major market players, growing awareness about fecal biomarker tests among healthcare professionals and patients, and availability of advanced healthcare facilities. Increasing incidence of gastrointestinal disorders like IBD further drives the demand for fecal calprotectin tests in North America.

The Asia Pacific region is expected to grow at the fastest pace during the forecast period owing to improving access to diagnosis and treatment, rising healthcare expenditure, increasing focus on early disease detection in large populous countries like China and India. Moreover, greater adoption of advanced diagnostic technologies and growing awareness regarding innovative biomarkers like fecal calprotectin are contributing to the regional market growth.

 

Get more insights on Fecal Calprotectin Test Market

What's your reaction?

Comments

https://www.timessquarereporter.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!

Facebook Conversations